Expanded Resources for Emerging Entrepreneurs
Turning a scientific breakthrough into a real therapy takes more than strong science. Emerging life sciences companies must also navigate fundraising, regulatory pathways, and the right partnerships as they move toward clinical and commercial milestones.
To help address these needs, the Biotechnology Innovation Organization (BIO) has introduced several new resources for its members designed to support emerging companies across fundraising, regulatory insight, and investor engagement. LaunchBio is proud to collaborate with BIO on one of these new initiatives while helping connect entrepreneurs to the broader set of tools now available to BIO member companies. These offerings include:
Investor Connect Plus, A LaunchBio x BIO partnership
LaunchBio is proud to partner with BIO on Investor Connect Plus, an exclusive investor access program designed specifically for BIO member companies seeking aligned institutional and strategic investment. Building on LaunchBio’s established Investor Connect programming, Investor Connect Plus is designed for more mature, investor-ready companies with validated science, demonstrated progress, and clearly defined capital strategies.
Through the program, participating companies are matched with institutional and strategic investors actively deploying capital across the life sciences sector. Each month, curated one-to-one meetings are arranged based on alignment in stage, sector, and investment thesis, helping move conversations beyond introductory exposure toward focused fundraising discussions.
By combining LaunchBio’s curated investor engagement platform and national investor network with BIO’s global member ecosystem, Investor Connect Plus creates a differentiated capital access pathway for companies navigating later stages of growth.
BRIDGE for BIO Regulatory Issue Data Gathering & Engagement
Companies often encounter shifting expectations that can affect the predictability and efficiency of the regulatory review process. To help address this challenge, BIO has introduced BRIDGE (BIO Regulatory Issue Data Gathering & Engagement). The initiative is designed to move beyond anecdotal reporting and instead establish a structured framework for collecting member-reported data on regulatory issues affecting the review and approval of innovative drugs and biologics regulated by the FDA.
Through BRIDGE, BIO will:
- Systematically collect information on regulatory roadblocks from member companies
- Aggregate insights to identify recurring trends and challenges
- Engage with FDA leadership when necessary to improve visibility into areas of regulatory friction
BRIDGE is part of a broader effort by BIO’s Science & Regulatory Affairs team to support regulatory reform and improve transparency for the biotechnology community. Participation is for BIO members only, voluntary, and at the company’s discretion.
Investor Database Access through Tracxn
In addition to capital access programming, BIO has also introduced a new partnership with Tracxn, providing member companies with complimentary access to a global investor intelligence platform. The database includes information on more than 250,000 active global investors, offering founders a powerful tool to identify and screen potential funding partners aligned with their sector and stage.
Through this partnership, BIO will provide private, pre-commercial member companies with one Tracxn account, enabling founders to research investors, track funding activity, and build more targeted outreach strategies as they prepare for fundraising.
Strengthening the Ecosystem for Emerging Innovators
From regulatory insight to investor access, these new offerings reflect BIO’s continued commitment to supporting the next generation of life sciences innovators. LaunchBio is excited to partner with BIO on Investor Connect Plus and to help connect founders within our community to the broader resources now available to BIO member companies.
As the life sciences landscape continues to evolve, strengthening the connections between entrepreneurs, investors, and ecosystem partners remains essential to accelerating the development of new therapies and technologies that improve human health.